MPI Stannous Diphosphonate
MPI Stannous Diphosphonate Brand names, MPI Stannous Diphosphonate Analogs
- Acetodiphosphonic acid
- Acide etidronique [INN-French]
- Acido etidronico [INN-Spanish]
- Acidum etidronicum [INN-Latin]
- Cintichem Technetium 99m Hedspa
- Dequest 2010
- Dequest 2015
- Dequest Z 010
- Didronel
- Didronel IV
- EHDP
- Etidronate Disodium
- Etidronic acid
- Etidronic acid [USAN:BAN:INN]
- Etidronsaeure
- Ferrofos 510
- HEDP
- Hydroxyethanediphosphonic acid
- MPI Stannous Diphosphonate
- Osteoscan
- Oxyethylidenediphosphonic acid
- Turpinal SL
MPI Stannous Diphosphonate Brand Names Mixture
- No information avaliable
MPI Stannous Diphosphonate Chemical_Formula
C24H25NO4
MPI Stannous Diphosphonate RX_link
http://www.rxlist.com/cgi/generic3/flavoxate.htm
MPI Stannous Diphosphonate fda sheet
MPI Stannous Diphosphonate msds (material safety sheet)
MPI Stannous Diphosphonate Synthesis Reference
No information avaliable
MPI Stannous Diphosphonate Molecular Weight
391.46 g/mol
MPI Stannous Diphosphonate Melting Point
No information avaliable
MPI Stannous Diphosphonate H2O Solubility
10 mg/L
MPI Stannous Diphosphonate State
Solid
MPI Stannous Diphosphonate LogP
4.636
MPI Stannous Diphosphonate Dosage Forms
Tablets (100 mg)
MPI Stannous Diphosphonate Indication
For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
MPI Stannous Diphosphonate Pharmacology
Flavoxate is a spasmolytic flavone derivative that acts by relaxing the smooth muscle in the urinary tract. Flavoxate is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Muscarinic receptors play an important role in several major cholin-ergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.
MPI Stannous Diphosphonate Absorption
Well absorbed from gastrointestinal tract.
MPI Stannous Diphosphonate side effects and Toxicity
The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.
MPI Stannous Diphosphonate Patient Information
MPI Stannous Diphosphonate Organisms Affected
Humans and other mammals
